<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nephrotoxicity of molecularly targeted agents and immunotherapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nephrotoxicity of molecularly targeted agents and immunotherapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nephrotoxicity of molecularly targeted agents and immunotherapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jaime R Merchan, MD, MMSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenar D Jhaveri, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3519476740"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Some anticancer therapies take advantage of molecular alterations that have been detected in certain types of cancer. These therapies are collectively referred to as molecularly targeted agents. However, many of these drugs have been associated with significant kidney complications, ranging from electrolyte disorders to acute kidney injury requiring dialysis [<a href="#rid1">1-3</a>].</p><p>This topic review will cover kidney toxicities seen with several classes of molecularly targeted and biologic agents. Nephrotoxicity of chemotherapy and immune checkpoint inhibitors is discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Kidney'</a>.)</p><p></p><p class="headingAnchor" id="H1248543003"><span class="h1">DOSING CONSIDERATIONS FOR NEPHROTOXICITY</span><span class="headingEndMark"> — </span>Some agents may require dose adjustments in patients with baseline kidney disease and those who develop kidney toxicity while on cancer treatment. When known, individual drug dosing guidelines and adjustments for kidney toxicity are available through the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p class="headingAnchor" id="H1136913344"><span class="h1">ALK INHIBITORS</span></p><p class="headingAnchor" id="H2194952856"><span class="h2">Crizotinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">Crizotinib</a> is a kinase inhibitor that is used to treat advanced anaplastic lymphoma kinase (ALK) fusion gene-positive non-small cell lung cancer. (See  <a class="medical medical_review" href="/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Crizotinib'</a>.)</p><p>Drug-induced reductions in glomerular filtration rate (GFR) have been reported in patients treated with <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a>, mostly during the first two weeks of therapy [<a href="#rid4">4</a>]. However, the early onset, small size of the change (24 percent), minimal cumulative effect, and rapid reversibility after treatment discontinuation all suggest that this is not a direct nephrotoxic effect of the drug. Some have suggested that the acute effects on creatinine clearance (CrCl) reflect an effect of the drug on creatinine excretion rather than a true reduction in GFR [<a href="#rid5">5</a>]. </p><p>However, rare cases of acute kidney injury (AKI) have been reported following treatment with <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a> [<a href="#rid6">6-8</a>]. In two such cases, kidney biopsy revealed evidence of acute tubular injury.</p><p>In addition, the development of complex kidney cysts (3 percent) has been described in patients treated with <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a> [<a href="#rid9">9-11</a>]. Both the formation of new cysts and progression of preexisting kidney cysts can occur. Cyst development appears to be reversible upon discontinuation of the drug, and spontaneous cyst regression with continuous crizotinib treatment has also been reported [<a href="#rid10">10</a>]. The mechanism by which crizotinib induces cyst formation and/or growth is unknown.</p><p>Hyponatremia and hypokalemia have also been reported with <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a> [<a href="#rid3">3,12</a>].</p><p class="headingAnchor" id="H450284326"><span class="h2">Other ALK inhibitors</span><span class="headingEndMark"> — </span>Other available anaplastic lymphoma kinase (ALK) inhibitors include <a class="drug drug_general" data-topicid="95046" href="/d/drug information/95046.html" rel="external">ceritinib</a>, <a class="drug drug_general" data-topicid="105868" href="/d/drug information/105868.html" rel="external">alectinib</a>, <a class="drug drug_general" data-topicid="112993" href="/d/drug information/112993.html" rel="external">brigatinib</a>, and <a class="drug drug_general" data-topicid="119539" href="/d/drug information/119539.html" rel="external">lorlatinib</a>. Increases in creatinine have been seen in 11 to 28 percent of patients treated with alectinib [<a href="#rid13">13,14</a>], and proteinuria has been reported with lorlatinib [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H2408645699"><span class="h1">ANTIANGIOGENIC AGENTS</span><span class="headingEndMark"> — </span>Angiogenesis inhibitors are used to treat a variety of cancers, such as renal cell carcinoma and colorectal cancer, among others. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a> and  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach"</a>.)</p><p>These agents, which block the vascular endothelial growth factor (VEGF) pathway, include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ligand inhibitors</strong>, which bind to and inhibit ligand binding to the VEGF receptor (VEGFR), thereby preventing activation of the receptor. Examples include <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> (or other biosimilars), <a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">ramucirumab</a>, and <a class="drug drug_general" data-topicid="17100" href="/d/drug information/17100.html" rel="external">aflibercept</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Receptor tyrosine kinase inhibitors (TKIs)</strong>, which block the intracellular domain of the VEGFR. Examples include <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="87456" href="/d/drug information/87456.html" rel="external">ponatinib</a>, <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a>, <a class="drug drug_general" data-topicid="16484" href="/d/drug information/16484.html" rel="external">vandetanib</a>, cabozantinib, <a class="drug drug_general" data-topicid="131053" href="/d/drug information/131053.html" rel="external">tivozanib</a>, and <a class="drug drug_general" data-topicid="143377" href="/d/drug information/143377.html" rel="external">fruquintinib</a>, among others.</p><p></p><p class="headingAnchor" id="H1287857744"><span class="h2">Class effects of antiangiogenic agents</span></p><p class="headingAnchor" id="H2358373207"><span class="h3">Proteinuria/nephrotic syndrome</span><span class="headingEndMark"> — </span>Proteinuria is a class effect of all VEGF inhibitors. <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">Bevacizumab</a>, <a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">ramucirumab</a>, <a class="drug drug_general" data-topicid="17100" href="/d/drug information/17100.html" rel="external">aflibercept</a>, and the small molecule antiangiogenic TKIs all produce asymptomatic proteinuria, occasionally causing nephrotic syndrome [<a href="#rid16">16-18</a>]. Hypertension frequently accompanies proteinuria. (See  <a class="medical medical_review" href="/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Hypertension'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence and mechanism</strong> – The overall incidence of mild proteinuria in patients treated with <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> ranges from 21 to up to 63 percent. However, grade 3 or 4 proteinuria  (<a class="graphic graphic_table graphicRef91255" href="/d/graphic/91255.html" rel="external">table 1</a>) (defined as 3+ on dipstick, &gt;3.5 g of protein/24 hours, or the nephrotic syndrome) affects approximately 2 percent of treated patients [<a href="#rid19">19</a>]. The incidence of proteinuria is not higher in patients who receive shorter bevacizumab infusions (ie, 10 versus 90 minutes) [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">Less data are available for <a class="drug drug_general" data-topicid="17100" href="/d/drug information/17100.html" rel="external">aflibercept</a>. In a phase III trial, proteinuria developed in 62 percent of patients treated with aflibercept plus chemotherapy (versus 41 percent of those treated with chemotherapy alone), and it was severe (grade 3 or 4) in 7.8 versus 1.2 percent [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">Among patients treated with <a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">ramucirumab</a>, the risk of proteinuria may be lower. In a meta-analysis of six placebo-controlled randomized trials, the incidence of all-grade proteinuria for ramucirumab versus placebo was 9.4 versus 3.1 percent, while the risk of severe (grade 3 or 4) proteinuria was 1.1 versus 0.04 percent [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1">Among patients treated with antiangiogenic TKIs, the incidence of mild and symptomatic proteinuria also ranges from 21 to 63 percent, but heavy proteinuria is reported in up to 6.5 percent of patients [<a href="#rid17">17</a>]. In a meta-analysis, the incidence of all-grade and high-grade proteinuria with VEGFR TKIs was 18.7 and 2.4 percent, respectively, with a corresponding increased risk of all-grade (odds ratio [OR] 2.92, 95% CI 1.09-7.82) and high-grade (OR 1.97, 95% CI 1.01-3.84) proteinuria when compared with controls [<a href="#rid23">23</a>]. The incidence of proteinuria with <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a> may be lower than with other agents (7 percent all grade in one trial, 1 percent grade 3 or 4) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">The exact mechanism underlying proteinuria is not known. Reports of kidney biopsies among patients with proteinuria receiving VEGF-targeted agents are sparse. In an observational study that included 100 patients who underwent kidney biopsies due to anti-VEGF treatment-related hypertension and proteinuria, the most common histologic findings were thrombotic microangiopathy (TMA) and minimal change disease and/or collapsing-like focal segmental glomerulosclerosis (MCN/cFSGS) in 73 and 27 patients, respectively [<a href="#rid25">25</a>]. While TMA was associated predominantly with VEGF ligand inhibitor therapy, MCN/cFSGS was associated with VEGF TKI therapy. The factors associated with the occurrence and severity of proteinuria are unknown. Preexisting kidney disease (including higher baseline urine protein levels and hypertension) and renal cell carcinoma, as compared with other malignant diseases, may be predisposing factors. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Patients with chronic kidney disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The implications of asymptomatic proteinuria from VEGF inhibitors are unknown, and it is possible that most cases have no clinical consequences. However, proteinuria has been linked to adverse cardiovascular outcomes and progression to end-stage kidney disease (ESKD) in patients with chronic kidney disease. As such, proteinuria is identified as a target for treatment in kidney diseases in general. (See  <a class="medical medical_review" href="/d/html/7181.html" rel="external">"Secondary factors and progression of chronic kidney disease", section on 'Albuminuria'</a>.)</p><p></p><p class="bulletIndent1">The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D939b5d1f-9fb2-4499-80ef-0607aa6b114e&amp;token=MgNA0H4pFebH733Bej56O4GI5fLpgRzk7iIVh6iYv6tbmervjGc7QbFrDOuwzLyaD%2BQSia3ek8jf9yumdvDMmRwynXinbeXIy7CceSOGer9UHUxe6uzNAmF4t1rKoO%2B9&amp;TOPIC_ID=114914" target="_blank">United States Prescribing Information</a> for <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> recommends intermittent monitoring for the development of proteinuria but does not provide specific recommendations, except temporary withholding of the drug if protein excretion is &gt;2 g per 24 hours, and permanent discontinuation for nephrotic syndrome [<a href="#rid26">26</a>]. However, this complication is uncommon, and many institutions do not routinely dipstick urine prior to each dose of bevacizumab.</p><p></p><p class="bulletIndent1">Baseline and periodic urinalyses are recommended during treatment with <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a>, and <a class="drug drug_general" data-topicid="131053" href="/d/drug information/131053.html" rel="external">tivozanib</a>, with treatment interruption or discontinuation for patients who develop moderate to severe proteinuria (defined as ≥3 g per 24 hours for pazopanib and ≥2 g per 24 hours for lenvatinib and tivozanib but undefined for axitinib). There are no guidelines for other VEGF TKIs; however, good clinical practice dictates baseline and periodic assessment of proteinuria for these agents as well.</p><p></p><p class="bulletIndent1">Although discontinuation of the antiangiogenic agent results in significant reduction in proteinuria, persistence is common [<a href="#rid27">27</a>]. For patients with persistent proteinuria, in the absence of specific therapy directed against the underlying disease, lowering of intraglomerular pressure, which may reduce protein excretion, may be achieved by the administration of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). However, there are no randomized controlled trials evaluating the benefit of these agents in patients with proteinuria due to antiangiogenic agents. (See  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Patients with proteinuria'</a>.)</p><p></p><p class="headingAnchor" id="H3011167230"><span class="h3">Thrombotic microangiopathy</span><span class="headingEndMark"> — </span>Rarely, cases of systemic drug-induced TMA have been reported with specific antiangiogenic agents (eg, <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>). Patients may present with microangiopathic hemolysis; kidney-only manifestations including acute kidney injury and/or hypertension, or proteinuria alone; or a more systemic TMA syndrome. Withdrawal of the offending agent is critical because drug-induced TMA can be fatal. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Drugs associated with DITMA'</a>.)</p><p>Management of drug-induced TMA is presented separately. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.)</p><p class="headingAnchor" id="H1450203768"><span class="h2">Other kidney toxicities</span><span class="headingEndMark"> — </span>Other kidney toxicities reported with specific antiangiogenic agents are discussed below.</p><p class="headingAnchor" id="H3510229852"><span class="h3">Lenvatinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">Lenvatinib</a> is an orally active inhibitor of several tyrosine kinases, including VEGFR, fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), RET, and KIT. In addition to proteinuria, a class effect of VEGF inhibitors, serious, including fatal, kidney failure or impairment can occur in patients treated with lenvatinib [<a href="#rid28">28-30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney function impairment occurred in 14 percent of patients receiving <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> (initial dose 24 mg daily) in the SELECT trial (disseminated thyroid cancer) and in 7 percent of patients receiving lenvatinib (initial dose 8 or 12 mg daily, depending on body weight) in the REFLECT trial (hepatocellular carcinoma) [<a href="#rid29">29</a>]. Grade 3 to 5 kidney failure or impairment occurred in 3 percent (disseminated thyroid cancer) and 2 percent (hepatocellular carcinoma) of patients, including one fatality in each study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In Study 205 (renal cell cancer), kidney function impairment or failure occurred in 18 percent of patients receiving <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> (18 mg daily) with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, including grade 3 in 10 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Others report three cases of biopsy-proven renal TMA in patients treated with <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, presenting as proteinuria with a stable serum creatinine [<a href="#rid30">30</a>].</p><p></p><p class="headingAnchor" id="H1764109011"><span class="h3">Regorafenib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">Regorafenib</a> is an orally administered inhibitor of angiogenic (including VEGFR 1 to 3), stromal, and oncogenic receptor tyrosine kinases.</p><p>In addition to hypertension and the proteinuria that is seen with other antiangiogenic TKIs, <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a> has been associated with several electrolyte abnormalities, including hypophosphatemia, hypocalcemia, hyponatremia, and hypokalemia [<a href="#rid24">24,31,32</a>]. These abnormalities are usually mild to moderate and do not require dose reductions or treatment interruptions. </p><p class="headingAnchor" id="H2381206349"><span class="h3">Sorafenib and sunitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">Sorafenib</a> and <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> have been associated with acute and chronic interstitial nephritis in case reports [<a href="#rid33">33-35</a>]. Sorafenib is also known to cause hypophosphatemia and hypocalcemia [<a href="#rid36">36</a>]. This effect has been attributed to vitamin D malabsorption and secondary hyperparathyroidism, although the precise mechanism for this is unclear [<a href="#rid37">37</a>]. Thus, in patients taking sorafenib, vitamin D, phosphorus, and calcium levels should be routinely monitored.</p><p class="headingAnchor" id="H3638046089"><span class="h3">Vandetanib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16484" href="/d/drug information/16484.html" rel="external">Vandetanib</a> is an orally active inhibitor of several tyrosine kinases, including RET, VEGFR, and epidermal growth factor receptor (EGFR). As noted in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525&amp;token=B5pIw8Y%2B2%2BkuzyRM3V3E%2BGuw706VvCKsBQo%2FF0jOtwBgxH%2BVBZVcqEN0w%2B4v5TwA0LZGSHgc571j38NfUjc0bLSJh0%2FNll3JzZtPh378DmNstyip697bnfJiPvlYM2m6&amp;TOPIC_ID=114914" target="_blank">United States Prescribing Information</a> for vandetanib, increases in creatinine during therapy occur in approximately 16 percent of patients and may be severe.</p><p><a class="drug drug_general" data-topicid="16484" href="/d/drug information/16484.html" rel="external">Vandetanib</a> has been associated with a number of electrolyte disturbances, such as hypocalcemia, hypomagnesemia, hypokalemia, hyponatremia, and hypercalcemia [<a href="#rid38">38,39</a>]. Hypertension has been reported in approximately 10 to 34 percent of patients [<a href="#rid38">38,40,41</a>]. </p><p><a class="drug drug_general" data-topicid="16484" href="/d/drug information/16484.html" rel="external">Vandetanib</a> has also been shown to have inhibitory activity on several human renal transporters, such as multidrug and toxin extrusion 1 and 2 (MATE-1 and MATE-2K), which are responsible for the clearance of multiple drugs and toxins. Inhibition of MATE-1 and MATE-2K at the apical membrane of the tubular cells might lead to decreased kidney clearance and increased nephrotoxicity of other coadministered agents, such as <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H1461924889"><span class="h1">BCL-2 INHIBITORS</span><span class="headingEndMark"> — </span>The B cell lymphoma-2 (BCL-2) inhibitor <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>, which is used in the treatment of refractory chronic lymphocytic leukemia, is associated with a particularly high incidence of tumor lysis syndrome (TLS), which can cause acute kidney injury and severe electrolyte abnormalities. A gradual, stepwise dose-escalation strategy has been introduced in an effort to reduce this risk. These issues are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors", section on 'Hematologic malignancies'</a> and  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'BCL2 inhibitors: Venetoclax'</a>.)</p><p class="headingAnchor" id="H344532474"><span class="h1">BCR::ABL AND KIT INHIBITORS</span><span class="headingEndMark"> — </span>There are several small molecule inhibitors of BCR::ABL, a tyrosine kinase that is the constitutively activated protein gene product of the Philadelphia chromosome in chronic myelogenous leukemia (CML); some also inhibit the tyrosine kinase receptor KIT (CD117) and platelet-derived growth factor receptor (PDGFR), which are constitutively activated in gastrointestinal stromal tumors (GIST).</p><p class="headingAnchor" id="H2527742259"><span class="h2">Imatinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">Imatinib</a> is a small molecule first-generation tyrosine kinase inhibitor (TKI) that targets BCR::ABL and KIT; the drug is commonly used for treatment of both CML and GIST. (See  <a class="medical medical_review" href="/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors"</a>.)</p><p>Acute and chronic kidney injury have been described in patients treated with extended-duration <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> for CML [<a href="#rid43">43-47</a>]. In one study, acute kidney injury (AKI) and chronic kidney disease occurred in 7 and 12 percent of patients, respectively; with long-term treatment, the mean decrease in estimated glomerular filtration rate (eGFR) was 2.77 mL/min/1.73 m<sup>2</sup> per year [<a href="#rid43">43</a>]. Potential mechanisms of injury include tumor lysis syndrome (TLS), acute tubular injury, and rhabdomyolysis; inhibition of tubular secretion of creatinine may also be a contributing factor to an observed rise in serum creatinine [<a href="#rid44">44,45,48-52</a>]. Kidney function impairment appears to be dose dependent, as higher doses have been associated with a higher incidence of tubular damage [<a href="#rid51">51</a>].</p><p>Hypophosphatemia can occur in patients treated with <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> [<a href="#rid53">53,54</a>], with one case series reporting an incidence of 51 percent [<a href="#rid53">53</a>]. The mechanism underlying hypophosphatemia is unclear, but it may be related to the inhibition of renal tubular reabsorption of phosphorus.</p><p>There is a single case report of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) from high-dose <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> in the literature. (See  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"</a>.)</p><p class="headingAnchor" id="H3342185451"><span class="h2">Dasatinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8852" href="/d/drug information/8852.html" rel="external">Dasatinib</a> is a second-generation TKI used mainly in patients with imatinib-resistant CML. It has effects on BCR::ABL as well as PDGFR and KIT. (See  <a class="medical medical_review" href="/d/html/4515.html" rel="external">"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy", section on 'Dasatinib'</a>.)</p><p>Rare cases of AKI have been reported with the use of <a class="drug drug_general" data-topicid="8852" href="/d/drug information/8852.html" rel="external">dasatinib</a> [<a href="#rid55">55-61</a>], including one patient who developed rhabdomyolysis [<a href="#rid59">59</a>] and others with thrombotic microangiopathy [<a href="#rid58">58,62</a>]. In addition, there have been reports of proteinuria and nephrotic syndrome [<a href="#rid60">60,61,63</a>]; in all cases, proteinuria resolved upon discontinuation of the drug or switching to <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>. Of the TKIs that target the BCR::ABL pathway, dasatinib is the only agent associated with the development of proteinuria. Some have suggested that dasatinib nephrotoxicity is primarily through its effect on glomerular podocytes and is independent of systemic or glomerular inhibition of vascular endothelial growth factor (VEGF) [<a href="#rid64">64,65</a>].</p><p class="headingAnchor" id="H1044248852"><span class="h2">Bosutinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="86371" href="/d/drug information/86371.html" rel="external">Bosutinib</a> is a dual TKI that targets both the ABL and SRC pathways; it does not target KIT or PDGFR. It is approved for treatment of refractory CML. (See  <a class="medical medical_review" href="/d/html/4515.html" rel="external">"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy", section on 'Bosutinib'</a>.)</p><p>Although there are no published cases of AKI, hypophosphatemia and an apparently reversible decline in GFR have been reported during long-term therapy with <a class="drug drug_general" data-topicid="86371" href="/d/drug information/86371.html" rel="external">bosutinib</a> [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H116270820"><span class="h2">Other agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nilotinib</strong> – <a class="drug drug_general" data-topicid="9448" href="/d/drug information/9448.html" rel="external">Nilotinib</a> has not been reported to cause nephrotoxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ponatinib</strong> – <a class="drug drug_general" data-topicid="87456" href="/d/drug information/87456.html" rel="external">Ponatinib</a>, a multitargeted TKI with activity against the VEGF receptor, has been associated with the development of nephrotic syndrome and secondary focal segmental glomerulosclerosis in one case report [<a href="#rid66">66</a>].</p><p></p><p class="headingAnchor" id="H1514347373"><span class="h1">BRAF INHIBITORS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">Vemurafenib</a> and <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> are potent inhibitors of the kinase domain in the mutant <em>BRAF </em>gene. These agents are used to treat <em>BRAF</em> V600E mutant melanoma. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vemurafenib</strong> – An increase in serum creatinine concentration has been reported with <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, which generally occurs in the first two months of therapy. This appears to be caused, at least in part, by inhibition of tubular creatinine secretion [<a href="#rid67">67</a>]. This effect is generally reversible when vemurafenib is discontinued. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Toxicities of BRAF and MEK inhibitors'</a>.)</p><p></p><p class="bulletIndent1">Acute kidney injury (AKI) [<a href="#rid68">68-72</a>] and one case of Fanconi syndrome have also been reported with <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> [<a href="#rid68">68-70,73</a>]. The precise mechanism of kidney injury is unclear, but kidney biopsies, when performed, have shown evidence of acute tubular damage and interstitial fibrosis [<a href="#rid71">71,72</a>]. Vemurafenib-associated kidney injury appears to be more common in males [<a href="#rid71">71,72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dabrafenib</strong> – AKI can also occur with <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>, although the incidence appears to be less than that with <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> [<a href="#rid71">71</a>].</p><p></p><p>BRAF inhibitors (<a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>, <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="118325" href="/d/drug information/118325.html" rel="external">encorafenib</a>) are frequently used in combination with mitogen-activated extracellular kinase (MEK) inhibitors (eg, <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>, <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a>, <a class="drug drug_general" data-topicid="118324" href="/d/drug information/118324.html" rel="external">binimetinib</a>) for the treatment of various <em>BRAF</em> V600E mutated tumors. While nephrotoxicity has not been reported with MEK inhibitor monotherapy, the combination of BRAF and MEK inhibitors have been reported to cause kidney function impairment, hyponatremia, and rare cases of glomerulonephritis [<a href="#rid74">74-78</a>]. As an example, in one study of encorafenib plus binimetinib in metastatic <em>BRAF</em>-mutant melanoma, the incidence of increased creatinine as a laboratory abnormality was 93 percent [<a href="#rid26">26</a>], but severe (grade 3 to 4) increases were uncommon (4 percent)  (<a class="graphic graphic_table graphicRef91253" href="/d/graphic/91253.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef91255" href="/d/graphic/91255.html" rel="external">table 1</a>) [<a href="#rid78">78-80</a>].</p><p class="headingAnchor" id="H548423429"><span class="h1">BTK INHIBITORS</span></p><p class="headingAnchor" id="H4040676533"><span class="h2">Ibrutinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> is an orally active, covalent (irreversible) inhibitor of Bruton tyrosine kinase (BTK), a mediator of the B cell receptor signaling pathway that inhibits malignant B cell survival. The use of this agent to treat chronic lymphocytic leukemia is discussed separately. (See  <a class="medical medical_review" href="/d/html/83749.html" rel="external">"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p>Serious and potentially fatal cases of acute kidney injury (AKI) have occurred with <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> therapy [<a href="#rid81">81-83</a>]. In one report of 111 patients receiving ibrutinib for mantle cell lymphoma, AKI developed in three (2.7 percent) [<a href="#rid81">81</a>]. Overall, increases in serum creatinine levels of up to 1.5 times the upper limit of normal (ULN) and 1.5 to 3 times ULN have been reported in 67 and 9 percent of patients treated with ibrutinib, respectively [<a href="#rid82">82</a>]. The mechanism of this injury is unclear at this point, but tumor lysis syndrome (TLS) might be contributory. (See  <a class="medical medical_review" href="/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors"</a>.)</p><p class="headingAnchor" id="H1269976294"><span class="h2">Pirtobrutinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">Pirtobrutinib</a> is an orally active, non-covalent (reversible) inhibitor of BTK, a mediator of the B cell receptor signaling pathway that inhibits malignant B cell survival. The use of this agent to treat mantle cell lymphoma is discussed separately. (See  <a class="medical medical_review" href="/d/html/4735.html" rel="external">"Treatment of relapsed or refractory mantle cell lymphoma", section on 'Bruton tyrosine kinase inhibitors'</a>.)</p><p><a class="drug drug_general" data-topicid="140692" href="/d/drug information/140692.html" rel="external">Pirtobrutinib</a> has been reported to cause increased creatinine levels. In one study, the incidence of increased creatinine of any grade was 30 percent, but severe (grade 3 to 4) increases were uncommon (less than 2 percent) [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H2325000837"><span class="h1">CDK4/6 INHIBITORS</span><span class="headingEndMark"> — </span>The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors <a class="drug drug_general" data-topicid="99759" href="/d/drug information/99759.html" rel="external">palbociclib</a>, <a class="drug drug_general" data-topicid="112288" href="/d/drug information/112288.html" rel="external">ribociclib</a>, and <a class="drug drug_general" data-topicid="115098" href="/d/drug information/115098.html" rel="external">abemaciclib</a> are used in the care of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancer. (See  <a class="medical medical_review" href="/d/html/778.html" rel="external">"Treatment for hormone receptor-positive, HER2-negative advanced breast cancer"</a>.)</p><p>Between 10 and 25 percent of patients treated with <a class="drug drug_general" data-topicid="115098" href="/d/drug information/115098.html" rel="external">abemaciclib</a> have increased serum creatinine levels during therapy, whereas, to date, none of the clinical trials on <a class="drug drug_general" data-topicid="99759" href="/d/drug information/99759.html" rel="external">palbociclib</a> have reported increased serum creatinine levels [<a href="#rid85">85-91</a>]. In a post hoc analysis of the MONARCH I study, the rise in serum creatinine seen with abemaciclib was not accompanied by changes in other markers of kidney function such as blood urea nitrogen, cystatin C, or estimated glomerular filtration rate (eGFR) based on cystatin C [<a href="#rid92">92,93</a>]. The underlying mechanism and the extent of kidney damage related to this agent remain unclear. Another study found that patients receiving abemaciclib experienced a mild (approximately 10 to 40 percent) reversible increase in serum creatinine due to inhibition of tubular creatinine secretion. Data on other CDK4/6 inhibitors are limited, but a similar pathophysiology for elevated serum creatinine levels is likely. (See  <a class="medical medical_review" href="/d/html/2361.html" rel="external">"Drugs that elevate the serum creatinine concentration", section on 'Decreased secretion'</a>.)</p><p>Although creatinine levels typically remain elevated during <a class="drug drug_general" data-topicid="115098" href="/d/drug information/115098.html" rel="external">abemaciclib</a> treatment, they return to normal upon treatment discontinuation [<a href="#rid91">91</a>]. Dose adjustments of abemaciclib should not be based upon creatinine levels because they may not reflect true kidney function. If deterioration in kidney function is suspected, alternative measurements of kidney function (ie, levels of cystatin C and cystatin-based eGFR) can be obtained to distinguish true acute kidney injury (AKI) from impaired tubular creatinine secretion. (See  <a class="medical medical_review" href="/d/html/2359.html" rel="external">"Assessment of kidney function", section on 'eGFR from cystatin C'</a>.)</p><p class="headingAnchor" id="H1535999760"><span class="h1">EGFR INHIBITORS</span><span class="headingEndMark"> — </span>Inhibitors of the epidermal growth factor receptor (EGFR) pathway include small molecule tyrosine kinase inhibitors (TKIs) (<a class="drug drug_general" data-topicid="90144" href="/d/drug information/90144.html" rel="external">afatinib</a>, <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, and <a class="drug drug_general" data-topicid="8712" href="/d/drug information/8712.html" rel="external">gefitinib</a>) and monoclonal antibodies targeting the EGFR (<a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> and <a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">panitumumab</a>). These agents are used in the treatment of advanced colorectal cancer and head and neck cancer. (See  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Benefit of cetuximab and panitumumab'</a> and  <a class="medical medical_review" href="/d/html/3364.html" rel="external">"Treatment of metastatic and recurrent head and neck cancer"</a>.)</p><p class="headingAnchor" id="H2372328215"><span class="h2">Anti-EGFR monoclonal antibodies</span><span class="headingEndMark"> — </span>Monoclonal antibodies targeting the EGFR (<a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> and <a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">panitumumab</a>) are all associated with the progressive development of hypomagnesemia due to renal magnesium wasting [<a href="#rid94">94-99</a>].</p><p>The mechanism for this has been attributed to inhibition of EGFR signaling at the distal convoluted tubule, which, under normal physiologic conditions, plays an important role in regulating transepithelial magnesium transport. (See  <a class="medical medical_review" href="/d/html/844.html" rel="external">"Regulation of magnesium balance", section on 'Distal reabsorption'</a>.)</p><p>The frequency of this complication with <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> was illustrated in a meta-analysis of 19 clinical reports totaling 3081 patients assigned to cetuximab-based treatment [<a href="#rid100">100</a>]. Thirty-seven percent of patients developed hypomagnesemia of any grade during therapy; the incidence of grade 3 or 4 hypomagnesemia (&lt;0.9 mg/dL) was 5.6 percent. Whether the severity of hypomagnesemia represents a surrogate marker of oncologic outcomes in patients treated with cetuximab for advanced colorectal cancer (as is the development of an acneiform rash) is unclear; the data are conflicting [<a href="#rid101">101-103</a>]. </p><p>Hypomagnesemia resolves after treatment is discontinued. Hypomagnesemia may lead to secondary hypocalcemia, and periodic monitoring of serum magnesium and calcium levels is warranted during therapy and for at least eight weeks after treatment discontinuation. (See  <a class="medical medical_review" href="/d/html/848.html" rel="external">"Hypomagnesemia: Clinical manifestations of magnesium depletion"</a> and  <a class="medical medical_review" href="/d/html/844.html" rel="external">"Regulation of magnesium balance"</a>.)</p><p><a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">Cetuximab</a> also causes hypokalemia in approximately 8 percent of patients [<a href="#rid104">104</a>]. The exact mechanism underlying this complication is not established; magnesium deficiency may contribute. Thus, periodic monitoring of serum potassium is warranted during therapy with cetuximab. (See  <a class="medical medical_review" href="/d/html/2341.html" rel="external">"Causes of hypokalemia in adults"</a>.)</p><p>In addition, other kidney toxicities have been reported with <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a>, including acute kidney injury (AKI) [<a href="#rid3">3,105</a>], one case report of diffuse proliferative glomerulonephritis [<a href="#rid106">106</a>], and another case report of nephrotic syndrome [<a href="#rid107">107</a>]. The cause of AKI is not clear. EGFR, which is mainly expressed in the distal and collecting tubules, is involved in maintaining tubular integrity, and activation of EGFR leads to growth and generation of tubular epithelial cells after acute tubular injury. In patients prone to experiencing kidney injury, treatment with anti-EGFR agents might be a "second hit" for the development of AKI.</p><p>Hyponatremia has also been described in patients treated with <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a>. In a systematic review and meta-analysis of 13 phase III studies including 6670 patients treated with eight targeted agents, all-grade hyponatremia occurred most commonly in patients treated with the combination of brivanib and cetuximab (63.4 percent) [<a href="#rid108">108</a>]. Patients treated with cetuximab had the highest incidence of high-grade hyponatremia (34.8 percent).</p><p class="headingAnchor" id="H1458609374"><span class="h2">EGFR tyrosine kinase inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="90144" href="/d/drug information/90144.html" rel="external">Afatinib</a>, <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="8712" href="/d/drug information/8712.html" rel="external">gefitinib</a>, <a class="drug drug_general" data-topicid="119171" href="/d/drug information/119171.html" rel="external">dacomitinib</a>, <a class="drug drug_general" data-topicid="105441" href="/d/drug information/105441.html" rel="external">osimertinib</a>, and <a class="drug drug_general" data-topicid="132715" href="/d/drug information/132715.html" rel="external">mobocertinib</a> are all used in the treatment of non-small cell lung cancer. (See  <a class="medical medical_review" href="/d/html/4630.html" rel="external">"Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor"</a>.)</p><p>Electrolyte disorders (such as hyponatremia, hypocalcemia, hypomagnesemia, hypokalemia, and hypophosphatemia) have been reported with all EGFR TKIs, although the incidence overall seems less than that with the EGFR monoclonal antibodies [<a href="#rid3">3</a>]. Such electrolyte abnormalities should be corrected prior to initiating therapy to reduce the risk of cardiotoxicity seen with some of these agents (eg, <a class="drug drug_general" data-topicid="132715" href="/d/drug information/132715.html" rel="external">mobocertinib</a>). Further details are discussed separately. (See  <a class="medical medical_review" href="/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines", section on 'Osimertinib and mobocertinib'</a>.)</p><p>In addition, there are case reports of nephrotic syndrome with kidney biopsy findings consistent with minimal change disease and membranous nephropathy occurring in patients treated with <a class="drug drug_general" data-topicid="8712" href="/d/drug information/8712.html" rel="external">gefitinib</a> [<a href="#rid109">109-111</a>].</p><p class="headingAnchor" id="H565378583"><span class="h1">FGFR INHIBITORS</span><span class="headingEndMark"> — </span>Fibroblast growth factor receptor (FGFR) inhibitors, such as <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a>, are used in the treatment of metastatic bladder cancer. (See  <a class="medical medical_review" href="/d/html/3000.html" rel="external">"Treatment of metastatic urothelial carcinoma of the bladder and urinary tract"</a>.)</p><p>All inhibitors of FGFR (eg, <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a>, <a class="drug drug_general" data-topicid="131754" href="/d/drug information/131754.html" rel="external">infigratinib</a>, and <a class="drug drug_general" data-topicid="127947" href="/d/drug information/127947.html" rel="external">pemigatinib</a>) cause hyperphosphatemia as a class effect. This is because the FGFR pathway is important for phosphate homeostasis via feedback mechanisms that involve fibroblast growth factor (FGF) 23, 1,25-dihydroxyvitamin D, and parathyroid hormone [<a href="#rid112">112-117</a>]. (See  <a class="medical medical_review" href="/d/html/828.html" rel="external">"Overview of the causes and treatment of hyperphosphatemia", section on 'Increased tubular reabsorption of phosphate'</a>.)</p><p>Hyperphosphatemia can lead to soft tissue mineralization, cutaneous calcifications, calcinosis, and non-uremic calciphylaxis [<a href="#rid118">118</a>]. Although hyperphosphatemia occurs in over 60 percent of treated patients, it is generally mild (grade 1 or 2  (<a class="graphic graphic_table graphicRef91252" href="/d/graphic/91252.html" rel="external">table 3</a>)). In general, hyperphosphatemia occurs early after treatment initiation (average 15 to 20 days) and can be managed with a low phosphate diet, concomitant phosphate binders, dose reduction, and/or dose interruption. Although hypophosphatemia has also been reported [<a href="#rid114">114</a>], this might have resulted from the continued use of a low phosphate diet or phosphate binders for hyperphosphatemia during off-treatment times or from negative-feedback effects on phosphate homeostasis.</p><p>Acute kidney injury (AKI) has also been reported in patients treated with FGFR inhibitors [<a href="#rid119">119-122</a>]. In one study, 6 percent of patients treated with <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a> experienced AKI, with 2 percent having grade 3 or higher AKI [<a href="#rid120">120</a>]. In a case report describing AKI with rogaratinib, a selective pan-FGFR tyrosine kinase inhibitor (TKI), kidney biopsy showed acute tubular necrosis [<a href="#rid119">119</a>]. AKI improved with treatment discontinuation, and reintroduction of therapy at a lower dose level did not prompt recurrence of kidney injury.</p><p class="headingAnchor" id="H2112553951"><span class="h1">HER2 INHIBITORS</span><span class="headingEndMark"> — </span>Systemic agents that inhibit human epidermal growth factor receptor 2 (HER2) are used to treat a variety of malignancies that express HER2, such as breast cancer, gastric cancer, colorectal cancer, and salivary gland tumors. (See  <a class="medical medical_review" href="/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer"</a> and  <a class="medical medical_review" href="/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS wild-type, HER2 overexpressors'</a> and  <a class="medical medical_review" href="/d/html/121739.html" rel="external">"Second and later-line systemic therapy for advanced unresectable and metastatic esophageal and gastric cancer", section on 'HER2-positive adenocarcinoma'</a> and  <a class="medical medical_review" href="/d/html/3382.html" rel="external">"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease", section on 'HER2 overexpression'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">Trastuzumab</a> is a recombinant humanized monoclonal antibody that binds to the extracellular domain of HER2 and inhibits proliferation of cells that overexpress the HER2 protein. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="85639" href="/d/drug information/85639.html" rel="external">Pertuzumab</a> is a humanized monoclonal antibody that binds the extracellular dimerization domain of HER2 and prevents it from binding to itself or to other members of the epidermal growth factor receptor (EGFR) family. Pertuzumab is typically administered in combination with <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> rather than as a single agent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="88427" href="/d/drug information/88427.html" rel="external">Ado-trastuzumab emtansine</a> (T-DM1) is an antibody-drug conjugate consisting of <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> linked to the microtubule inhibitor emtansine (DM1), a derivative of maytansine. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10093" href="/d/drug information/10093.html" rel="external">Lapatinib</a> is a dual tyrosine kinase inhibitor (TKI) that interrupts both the EGFR (erbB1) and HER2 (erbB2) pathways. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="127946" href="/d/drug information/127946.html" rel="external">Tucatinib</a> is an oral TKI that is selective for the kinase domain of HER2, with minimal inhibition of EGFR. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="126410" href="/d/drug information/126410.html" rel="external">Fam-trastuzumab deruxtecan</a> is an antibody-drug conjugate composed of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.</p><p></p><p>There are no published case reports of nephrotoxicity with either <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> or <a class="drug drug_general" data-topicid="85639" href="/d/drug information/85639.html" rel="external">pertuzumab</a>. </p><p>Rare cases of fetal nephrotoxicity associated with anhydramnios have been described with <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> administered during pregnancy; in three cases, there was spontaneous improvement after discontinuation of trastuzumab [<a href="#rid123">123-125</a>]. (See  <a class="medical medical_review" href="/d/html/15801.html" rel="external">"Gestational breast cancer: Treatment", section on 'Anti-HER2 therapies'</a>.)</p><p>Patients treated with <a class="drug drug_general" data-topicid="88427" href="/d/drug information/88427.html" rel="external">ado-trastuzumab emtansine</a> can develop hypokalemia during therapy (overall incidence approximately 10 percent of any grade, 2 to 3 percent grade 3 or 4  (<a class="graphic graphic_table graphicRef91252" href="/d/graphic/91252.html" rel="external">table 3</a>)) [<a href="#rid126">126,127</a>].</p><p>In a phase II trial of <a class="drug drug_general" data-topicid="10093" href="/d/drug information/10093.html" rel="external">lapatinib</a>, seven patients experienced treatment-related grade 3 toxicity, two of whom developed hyponatremia [<a href="#rid128">128</a>]. An analysis of the US Food and Drug Administration (FDA) Adverse Event Reporting System identified a total of 171 kidney adverse events reported between 2011 and 2015, most of which were cases of hypokalemia (61 cases) and acute kidney injury (AKI) (48 cases); a few cases of hypertension, hypomagnesemia, and hyponatremia were also reported [<a href="#rid3">3</a>].</p><p>Increased creatinine of any grade has been reported with <a class="drug drug_general" data-topicid="127946" href="/d/drug information/127946.html" rel="external">tucatinib</a> (14 to 58 percent) and <a class="drug drug_general" data-topicid="126410" href="/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a> (16 percent), but severe (grade 3 to 4) toxicity is extremely rare for both agents (not reported for tucatinib and 1 percent for fam-trastuzumab deruxtecan) [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H993681564"><span class="h1">MTOR INHIBITORS</span><span class="headingEndMark"> — </span>The extensive experience with mechanistic (mammalian) target of rapamycin (mTOR) inhibitors in solid organ transplantation as well as advances in our understanding of the role of the Akt/mTOR pathway in the maintenance of podocyte viability have led to concerns about short- and long-term nephrotoxicity with these agents [<a href="#rid129">129,130</a>]. (See  <a class="medical medical_review" href="/d/html/3091.html" rel="external">"Biology of glomerular podocytes", section on 'Direct podocyte injury'</a>.)</p><p>Proteinuria and, more rarely, kidney function impairment have been reported in patients taking mTOR inhibitors. The phenomena appear to be dose dependent and reversible with cessation of the medication. These issues are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors", section on 'Kidney function'</a>.)</p><p><a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">Temsirolimus</a> is a parenterally administered rapamycin analog that functions as a competitive mTOR inhibitor. There are rare case reports of temsirolimus-associated glomerulopathy and acute tubular necrosis [<a href="#rid131">131,132</a>]. (See  <a class="medical medical_review" href="/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma"</a>.)</p><p class="headingAnchor" id="H187654320"><span class="h1">PEPTIDE RECEPTOR RADIOLIGAND THERAPY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="116519" href="/d/drug information/116519.html" rel="external">Lutetium Lu-177 dotatate</a> (<sup>177</sup>Lu-Dotatate) is a radiolabeled somatostatin analog that is approved for treatment of somatostatin-receptor-positive progressive gastrointestinal and pancreatic neuroendocrine tumors (NETs). (See  <a class="medical medical_review" href="/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Lutetium Lu-177 dotatate'</a> and  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion", section on 'Lutetium-177 dotatate'</a>.)</p><p>Kidney irradiation may result in glomerular damage. During each peptide receptor radioligand therapy (PRRT) treatment (which is administered every eight weeks for four doses), a four-hour intravenous infusion with an amino acid solution is needed (two hours prior to and two hours following each dose) to protect the kidneys from the radiation effects of the therapeutic radionuclide. The available data suggest that this protocol results in low rates of nephrotoxicity during therapy (1 percent with grade 2 increases in creatinine in one Dutch report [<a href="#rid133">133</a>]). Following treatment, the average annual decrease in creatinine clearance (CrCl) was 3.4 percent, but no patient had an annual decrease in kidney function of &gt;20 percent. No risk factors for kidney toxicity could be identified.</p><p>However, rates of nephrotoxicity may be higher depending on the means of assessment. An analysis of kidney function over time using technetium-99m (<sup>99m</sup>Tc) diethylenetriaminepentaacetic acid (DTPA) clearance to accurately assess glomerular filtration rate (GFR) in 74 consecutive patients with gastroenteropancreatic NETs undergoing PRRT with <sup>177</sup>Lu-Dotatate noted slight kidney function impairment (GFR loss &gt;2 mL/min/m<sup>2</sup> per year) in 43 percent [<a href="#rid134">134</a>]. By contrast, there was only one case of grade 3 or worse nephrotoxicity  (<a class="graphic graphic_table graphicRef91253" href="/d/graphic/91253.html" rel="external">table 2</a>) as assessed by serum creatinine (1.3 percent).</p><p class="headingAnchor" id="H213403592"><span class="h1">OTHER TARGETED AGENTS</span></p><p class="headingAnchor" id="H3310728118"><span class="h2">MET inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="128126" href="/d/drug information/128126.html" rel="external">Capmatinib</a> and <a class="drug drug_general" data-topicid="130698" href="/d/drug information/130698.html" rel="external">tepotinib</a> are mesenchymal-epithelial transition (MET) tyrosine kinase inhibitors (TKIs) that are both approved for treatment of advanced non-small cell lung cancer with specific <em>MET </em>mutations that lead to <em>MET </em>exon 14 skipping. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'MET abnormalities'</a>.)</p><p>Treatment with either agent may result in an asymptomatic rise in serum creatinine, which spontaneously returns to baseline upon discontinuation of the agent [<a href="#rid135">135,136</a>]. Inhibition of tubular creatinine secretion may explain this phenomenon.</p><p class="headingAnchor" id="H913133243"><span class="h2">PARP inhibitors</span><span class="headingEndMark"> — </span>Inhibitors of poly(ADP-ribose) polymerase (PARP) are approved for treatment of <em>BRCA</em>-mutated breast cancer, for platinum-sensitive relapsed epithelial ovarian cancer (regardless of <em>BRCA</em> mutation status), and as maintenance therapy for pancreatic cancer in patients with <em>BRCA1</em> or <em>BRCA2</em> mutations who have not progressed after platinum-based chemotherapy. (See  <a class="medical medical_review" href="/d/html/16755.html" rel="external">"Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-sensitive disease", section on 'PARP inhibitors no longer used'</a> and  <a class="medical medical_review" href="/d/html/14227.html" rel="external">"ER/PR negative, HER2-negative (triple-negative) breast cancer", section on 'Patients with previous exposure to chemotherapy'</a> and  <a class="medical medical_review" href="/d/html/2475.html" rel="external">"Initial systemic chemotherapy for metastatic exocrine pancreatic cancer"</a>.)</p><p>Increases in creatinine have been reported in 25 to 30 percent of patients treated with <a class="drug drug_general" data-topicid="98761" href="/d/drug information/98761.html" rel="external">olaparib</a>, but most are mild (only 2 percent are grade 3  (<a class="graphic graphic_table graphicRef91253" href="/d/graphic/91253.html" rel="external">table 2</a>)) [<a href="#rid137">137</a>]. Deterioration in kidney function during therapy has also been reported with <a class="drug drug_general" data-topicid="112483" href="/d/drug information/112483.html" rel="external">niraparib</a> [<a href="#rid138">138</a>].</p><p class="headingAnchor" id="H582114992"><span class="h2">Oral gamma secretase inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="143558" href="/d/drug information/143558.html" rel="external">Nirogacestat</a> is an oral gamma secretase inhibitor that targets the NOTCH pathway. This agent is used to treat desmoid tumors. (See  <a class="medical medical_review" href="/d/html/7749.html" rel="external">"Desmoid tumors: Systemic therapy", section on 'Nirogacestat'</a>.)</p><p>Hyperphosphatemia is a class effect of oral gamma secretase inhibitors [<a href="#rid139">139</a>]. In a phase III trial of patients with desmoid tumors, hyperphosphatemia of any grade was observed in 42 percent of patients treated with <a class="drug drug_general" data-topicid="143558" href="/d/drug information/143558.html" rel="external">nirogacestat</a>, although severe (grade ≥3) hyperphosphatemia was uncommon (3 percent) [<a href="#rid140">140</a>]. </p><p class="headingAnchor" id="H2516722486"><span class="h2">Selinexor</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="121843" href="/d/drug information/121843.html" rel="external">Selinexor</a> is a selective inhibitor of the nuclear export protein exportin 1 (XPO1); it is approved in combination with <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> for the treatment of multiply relapsed or refractory multiple myeloma and for relapsed/refractory diffuse large B cell lymphoma. (See  <a class="medical medical_review" href="/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse", section on 'Selinexor'</a> and  <a class="medical medical_review" href="/d/html/132087.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit", section on 'Selinexor'</a>.)</p><p><a class="drug drug_general" data-topicid="121843" href="/d/drug information/121843.html" rel="external">Selinexor</a> can cause hyponatremia, which may be severe [<a href="#rid141">141-143</a>]. In an integrated safety analysis of 437 patients enrolled in clinical trials of selinexor in multiple myeloma, hyponatremia (defined as serum sodium &lt;135 mmol/L) was observed in 138 (32 percent), and 83 (19 percent) had grade ≥3 hyponatremia  (<a class="graphic graphic_table graphicRef91252" href="/d/graphic/91252.html" rel="external">table 3</a>) [<a href="#rid143">143</a>].</p><p>The mechanism of hyponatremia is not yet elucidated.</p><p class="headingAnchor" id="H24219596"><span class="h1">IMMUNOTHERAPIES</span></p><p class="headingAnchor" id="H3549083567"><span class="h2">Bispecific T-cell engagers</span><span class="headingEndMark"> — </span>Bispecific T-cell engagers (BiTEs) are antibodies that function as linkers between T cells and specific target antigens. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Bispecific T cell engagers'</a>.)</p><p>Examples of BiTEs used in clinical practice include <a class="drug drug_general" data-topicid="139997" href="/d/drug information/139997.html" rel="external">teclistamab</a>, <a class="drug drug_general" data-topicid="142431" href="/d/drug information/142431.html" rel="external">elranatamab</a>, <a class="drug drug_general" data-topicid="142419" href="/d/drug information/142419.html" rel="external">talquetamab</a>, and <a class="drug drug_general" data-topicid="98582" href="/d/drug information/98582.html" rel="external">blinatumomab</a>. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Bispecific antibodies'</a> and  <a class="medical medical_review" href="/d/html/4518.html" rel="external">"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults", section on 'Blinatumomab'</a>.)</p><p>BiTes are commonly associated with cytokine release syndrome (CRS), which can result in multiorgan dysfunction, including acute kidney injury (AKI). As an example, in a phase I trial of patients with treatment-refractory multiple myeloma treated with <a class="drug drug_general" data-topicid="139997" href="/d/drug information/139997.html" rel="external">teclistamab</a>, CRS was observed in a majority (72 percent) of patients [<a href="#rid144">144</a>]. The evaluation and management of BiTE-associated CRS is discussed separately. (See  <a class="medical medical_review" href="/d/html/118012.html" rel="external">"Cytokine release syndrome (CRS)", section on 'Bi-specific antibody-associated CRS'</a>.)</p><p class="headingAnchor" id="H1934558675"><span class="h2">CAR-T cell therapy</span><span class="headingEndMark"> — </span>Chimeric antigen receptor modified (CAR)-T cells are a form of genetically modified autologous immunotherapy. The patient's T cells are collected from blood and modified to express a CAR that is specific for a tumor antigen, followed by <em>ex vivo</em> expansion and then re-infusion back to the patient. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'CAR-T cells'</a>.)</p><p>CAR-T cell therapy is used to treat certain hematologic malignancies including leukemia, lymphoma, and multiple myeloma. Examples that are used in clinical practice include CAR-T cells directed against CD19 (<a class="drug drug_general" data-topicid="115350" href="/d/drug information/115350.html" rel="external">axicabtagene ciloleucel</a>, <a class="drug drug_general" data-topicid="129101" href="/d/drug information/129101.html" rel="external">brexucabtagene autoleucel</a>, <a class="drug drug_general" data-topicid="130728" href="/d/drug information/130728.html" rel="external">lisocabtagene maraleucel</a>, <a class="drug drug_general" data-topicid="131455" href="/d/drug information/131455.html" rel="external">loncastuximab tesirine</a>, <a class="drug drug_general" data-topicid="114674" href="/d/drug information/114674.html" rel="external">tisagenlecleucel</a>) and BCMA (<a class="drug drug_general" data-topicid="135088" href="/d/drug information/135088.html" rel="external">ciltacabtagene autoleucel</a>, idelcabtagene vicleucel). (See  <a class="medical medical_review" href="/d/html/4518.html" rel="external">"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults", section on 'CAR-T'</a> and  <a class="medical medical_review" href="/d/html/132087.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit", section on 'Chimeric antigen receptor T cell therapy'</a> and  <a class="medical medical_review" href="/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse", section on 'Chimeric antigen receptor T cells'</a>.)</p><p>In published trials of CD19-directed CAR-T cell therapy, a CRS has been reported in over 40 percent of patients, regardless of the disease studied or the construct of the CAR-T cells [<a href="#rid145">145-147</a>]. CRS can result in multiorgan dysfunction, including AKI [<a href="#rid148">148,149</a>]. The release of high concentrations of cytokines can lead to vasodilation, decreased cardiac output, and intravascular volume depletion due to increased vascular permeability and third spacing of fluids, all of which cause reduced perfusion to the kidneys and AKI. The rise in serum creatinine is observed approximately 7 to 10 days postinfusion [<a href="#rid150">150,151</a>]. Prerenal AKI and/or acute tubular injury may develop in this setting depending upon the severity of hypotension and its duration. (See  <a class="medical medical_review" href="/d/html/118012.html" rel="external">"Cytokine release syndrome (CRS)"</a>.)</p><p>In a systematic review of 22 studies including 3376 patients, the incidence of CRS among patients receiving CAR-T cell therapies was 75 percent, the overall estimated incidence of AKI was 19 percent, and the estimated incidence of AKI requiring kidney replacement therapy was 4 percent [<a href="#rid152">152</a>]. A subgroup analysis found that the incidence of AKI was higher among children and young adults compared with adults (22 versus 17 percent).</p><p>In this analysis, most patients had received <a class="drug drug_general" data-topicid="115350" href="/d/drug information/115350.html" rel="external">axicabtagene ciloleucel</a>, a CD19-targeting CAR-T that has a CD28 costimulatory domain and is characterized by rapid T-cell expansion and robust inflammatory cytokine secretion. Use of a different agent, <a class="drug drug_general" data-topicid="114674" href="/d/drug information/114674.html" rel="external">tisagenlecleucel</a>, that targets the same epitope of CD19 but has a different costimulatory domain and a reduced inflammatory profile, may be associated with lower toxicity rates, including AKI [<a href="#rid148">148,153</a>].</p><p>Besides age, other potential risk factors for AKI after CAR T-cell therapy are lower baseline kidney function at CAR-T cell initiation, exposure to intravenous contrast material, and a progressive increase in markers of tumor lysis or use of higher total doses of glucocorticoids or <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> after CAR-T cell infusion [<a href="#rid154">154</a>].</p><p>The reversibility of AKI was addressed in a single-institution retrospective review of 46 adult patients with non-Hodgkin lymphoma treated with CAR-T cell therapy over a one-year period, in which the cumulative incidence of any grade AKI by day 100 was 30 percent, mostly grade 1 (21.7 percent) [<a href="#rid148">148</a>]. No patient developed severe AKI necessitating kidney replacement therapy. Most patients recovered, with kidney function returning to baseline within 30 days.</p><p>Electrolyte disorders have also been reported in patients undergoing CAR-T cell therapy. They may include hyperphosphatemia and hyperkalemia, attributable to tumor lysis syndrome (TLS), but also hypokalemia and hypophosphatemia, which appear unrelated to TLS. The mechanism is not clearly defined. (See  <a class="medical medical_review" href="/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H3105831933"><span class="h2">Immune checkpoint inhibitors</span><span class="headingEndMark"> — </span>Immune checkpoint inhibitors (ICIs) are used to treat a variety of malignancies. These antibodies inhibit the following targets to enhance the immune system as part of cancer therapy (see  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Programmed cell death 1 receptor (PD-1) and its ligand, programmed cell death 1 ligand (PD-L1)</p><p class="bulletIndent1"><span class="glyph">●</span>Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)</p><p></p><p>ICIs have a unique spectrum of side effects termed immune-related adverse events. Further details on these and other kidney toxicities seen with ICIs are discussed separately. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Kidney'</a>.)</p><p class="headingAnchor" id="H1091273655"><span class="h2">Interleukin-2</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9413" href="/d/drug information/9413.html" rel="external">Recombinant human interleukin-2</a> (IL-2) can induce a relatively severe capillary leak syndrome, leading to edema, plasma volume depletion, and a reversible fall in glomerular filtration rate (GFR) [<a href="#rid155">155-157</a>]. As an example, in one study of 199 consecutive patients, most patients experienced oliguria, hypotension, and weight gain, and 13 percent of cycles were discontinued because of a substantial rise in the plasma creatinine concentration (from 1.2 to 2.7 mg/dL [106 to 238 micromol/L]) [<a href="#rid157">157</a>]. Poor kidney function promptly reversed after cessation of therapy.</p><p>It has been proposed that plasma volume depletion is responsible for the development of AKI. Although the clinical course and improvement in creatinine clearance (CrCl) and urine output following low-dose <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> [<a href="#rid158">158</a>] are compatible with this hypothesis, the observations that renal plasma flow is normal in affected patients [<a href="#rid155">155</a>] and that the urinalysis may reveal red cells, white cells, granular casts, and modest proteinuria [<a href="#rid156">156</a>] suggest that there may also be some direct kidney injury.</p><p>Patients with normal kidney function before treatment usually recover within the first week after discontinuing therapy. Patients with underlying kidney function impairment may take longer periods of time to recover from the kidney failure.</p><p>Therapy for kidney failure secondary to IL-2 treatment is supportive. It is directed at maintaining intravascular volume and stabilizing hemodynamic parameters, as well as avoiding other potential nephrotoxic agents. Preventive measures include a strict selection of patients who are candidates for IL-2 therapy. Older patients, patients with underlying kidney failure, and patients taking nephrotoxic agents are at higher risk for complications such as capillary leak syndrome and prerenal azotemia. (See  <a class="medical medical_review" href="/d/html/15407.html" rel="external">"Interleukin 2 and experimental immunotherapy approaches for advanced melanoma", section on 'Interleukin 2'</a>.)</p><p class="headingAnchor" id="H1665666690"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Some molecularly targeted agents and immunotherapies have been associated with significant kidney complications. The kidney toxicities of different drug classes are described in detail above. Selected agents are highlighted below.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing considerations</strong> – Some agents may require dose adjustments in patients with baseline kidney disease and those who develop kidney toxicity while on cancer treatment. When known, individual drug dosing guidelines and adjustments for kidney toxicity are available through the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. (See <a class="local">'Dosing considerations for nephrotoxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecularly targeted agents</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antiangiogenic agents</strong> – Antiangiogenic agents block the vascular endothelial growth factor (VEGF) pathway. These agents include <strong>ligand inhibitors</strong>, which bind to and inhibit ligand binding to the VEGF receptor (VEGFR), thereby preventing activation of the receptor, and <strong>receptor tyrosine kinase inhibitors (TKIs)</strong>, which block the intracellular domain of the VEGFR. Specific nephrotoxic class effects of antiangiogenic agents include: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Proteinuria/nephrotic syndrome</strong> – The overall incidence of proteinuria ranges from 21 to 63 percent, but severe (grade 3 or 4) proteinuria  (<a class="graphic graphic_table graphicRef91255" href="/d/graphic/91255.html" rel="external">table 1</a>) is uncommon. Patients treated with these agents should be intermittently monitored for proteinuria; treatment interruption or discontinuation may be indicated for moderate to severe proteinuria. (See <a class="local">'Proteinuria/nephrotic syndrome'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Thrombotic microangiopathy (TMA)</strong> – TMA is rare but has been reported with specific antiangiogenic agents (eg, <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>). Patients may present with microangiopathic hemolysis; kidney-only manifestations including acute kidney injury (AKI) and/or hypertension, or proteinuria alone; or a more systemic TMA syndrome. Withdrawal of the offending agent is critical because drug-induced TMA can be fatal. (See <a class="local">'Thrombotic microangiopathy'</a> above and  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CDK4/6 inhibitors</strong> – The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor <a class="drug drug_general" data-topicid="115098" href="/d/drug information/115098.html" rel="external">abemaciclib</a> results in increased serum creatinine levels in 10 to 25 percent of patients, which is likely related to inhibition of tubular creatinine secretion. These creatinine levels typically remain elevated during therapy and return to normal upon treatment discontinuation. If deterioration in kidney function is suspected, alternative measurements of kidney function (ie, levels of cystatin C and cystatin-based estimated glomerular filtration rate (eGFR)) can be obtained to distinguish true AKI from impaired tubular creatinine secretion. (See <a class="local">'CDK4/6 inhibitors'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>EGFR inhibitors</strong> – Hypomagnesemia is common with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (<a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> and <a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">panitumumab</a>). Other electrolyte disorders (such as hyponatremia, hypocalcemia, hypomagnesemia, hypokalemia, and hypophosphatemia) have been reported with all EGFR TKIs. (See <a class="local">'EGFR inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>FGFR inhibitors</strong> – Hyperphosphatemia is a class effect of fibroblast growth factor receptor (FGFR) inhibitors (eg, <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a>, <a class="drug drug_general" data-topicid="131754" href="/d/drug information/131754.html" rel="external">infigratinib</a>, and <a class="drug drug_general" data-topicid="127947" href="/d/drug information/127947.html" rel="external">pemigatinib</a>). (See <a class="local">'FGFR inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ibrutinib</strong> – <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> has been associated with serious and potentially fatal cases of AKI. The mechanism of injury is unclear, but tumor lysis syndrome (TLS) may be contributory. (See <a class="local">'Ibrutinib'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imatinib</strong> – <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">Imatinib</a> is associated with acute and chronic kidney injury when administered for extended durations and hyperphosphatemia. (See <a class="local">'Imatinib'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunotherapies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CAR-T cell therapy</strong> – Chimeric antigen receptor modified (CAR)-T cells can cause cytokine release syndrome (CRS) and AKI. Electrolyte disorders have also been reported, including hyperphosphatemia and hyperkalemia related to TLS but also hypokalemia and hypophosphatemia unrelated to TLS. (See <a class="local">'CAR-T cell therapy'</a> above and  <a class="medical medical_review" href="/d/html/118012.html" rel="external">"Cytokine release syndrome (CRS)", section on 'CAR-T cell-associated CRS'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immune checkpoint inhibitors</strong> – Immune checkpoint inhibitors have a unique spectrum of side effects termed immune-related adverse events. Further details are discussed separately. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Kidney'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Launay-Vacher V, Aapro M, De Castro G Jr, et al. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 2015; 26:1677.</a></li><li><a class="nounderline abstract_t">Jhaveri KD, Wanchoo R, Sakhiya V, et al. Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. Kidney Int Rep 2017; 2:108.</a></li><li><a class="nounderline abstract_t">Jhaveri KD, Sakhiya V, Wanchoo R, et al. Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System. Kidney Int 2016; 90:706.</a></li><li><a class="nounderline abstract_t">Brosnan EM, Weickhardt AJ, Lu X, et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 2014; 120:664.</a></li><li><a class="nounderline abstract_t">Camidge DR, Brosnan EM, DeSilva C, et al. Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate. J Thorac Oncol 2014; 9:1634.</a></li><li><a class="nounderline abstract_t">Izzedine H, Brocheriou I, Amoura Z, Mathian A. Acute Tubular Injury and Renal Arterial Myocyte Vacuolization Following Crizotinib Administration. Kidney Int Rep 2021; 6:526.</a></li><li><a class="nounderline abstract_t">Gastaud L, Ambrosetti D, Otto J, et al. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma. Lung Cancer 2013; 82:362.</a></li><li><a class="nounderline abstract_t">Martín Martorell P, Huerta Alvaro M, Solís Salguero MA, Insa Molla A. Crizotinib and renal insufficiency: a case report and review of the literature. Lung Cancer 2014; 84:310.</a></li><li><a class="nounderline abstract_t">Lin YT, Wang YF, Yang JC, et al. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol 2014; 9:1720.</a></li><li><a class="nounderline abstract_t">Klempner SJ, Aubin G, Dash A, Ou SH. Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Oncologist 2014; 19:1008.</a></li><li><a class="nounderline abstract_t">Schnell P, Bartlett CH, Solomon BJ, et al. Complex renal cysts associated with crizotinib treatment. Cancer Med 2015; 4:887.</a></li><li><a class="nounderline abstract_t">Izzedine H, El-Fekih RK, Perazella MA. The renal effects of ALK inhibitors. Invest New Drugs 2016; 34:643.</a></li><li class="breakAll">Cancer Drug information from Cancer Care Ontario http://cancercare.on.ca/cms/one.aspx?portalId=1377&amp;pageId=10760 (Accessed on September 14, 2017).</li><li><a class="nounderline abstract_t">Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017; 390:29.</a></li><li><a class="nounderline abstract_t">Lee CS, Wanchoo R, Seetharamu N. Lorlatinib induced proteinuria: A case report. J Oncol Pharm Pract 2021; 27:1037.</a></li><li><a class="nounderline abstract_t">Costero O, Picazo ML, Zamora P, et al. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant 2010; 25:1001.</a></li><li><a class="nounderline abstract_t">Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010; 46:439.</a></li><li><a class="nounderline abstract_t">Tomita Y, Uemura H, Fujimoto H, et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer 2011; 47:2592.</a></li><li><a class="nounderline abstract_t">Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010; 21:1381.</a></li><li><a class="nounderline abstract_t">Shah SR, Gressett Ussery SM, Dowell JE, et al. Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension. Ann Oncol 2013; 24:960.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30:3499.</a></li><li><a class="nounderline abstract_t">Arnold D, Fuchs CS, Tabernero J, et al. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol 2017; 28:2932.</a></li><li><a class="nounderline abstract_t">Zhang ZF, Wang T, Liu LH, Guo HQ. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS One 2014; 9:e90135.</a></li><li><a class="nounderline abstract_t">Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303.</a></li><li><a class="nounderline abstract_t">Izzedine H, Escudier B, Lhomme C, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore) 2014; 93:333.</a></li><li class="breakAll">DailyMed Drug Information: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on January 30, 2024).</li><li><a class="nounderline abstract_t">Patel TV, Morgan JA, Demetri GD, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008; 100:282.</a></li><li class="breakAll">Lenvatinib capsules. United States Prescribing Information. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e#_2_6__Dosage (Accessed on August 19, 2019).</li><li><a class="nounderline abstract_t">Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391:1163.</a></li><li><a class="nounderline abstract_t">Delsante M, Monroy-Trujillo JM, Carter-Monroe N, et al. Lenvatinib-related renal microangiopathy: a case series. Virchows Arch 2022; 480:467.</a></li><li><a class="nounderline abstract_t">Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009; 122:322.</a></li><li><a class="nounderline abstract_t">Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16:619.</a></li><li><a class="nounderline abstract_t">Winn SK, Ellis S, Savage P, et al. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant 2009; 24:673.</a></li><li><a class="nounderline abstract_t">Khurana A. Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother 2007; 5:341.</a></li><li><a class="nounderline abstract_t">Izzedine H, Brocheriou I, Rixe O, Deray G. Interstitial nephritis in a patient taking sorafenib. Nephrol Dial Transplant 2007; 22:2411.</a></li><li><a class="nounderline abstract_t">Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125.</a></li><li><a class="nounderline abstract_t">Bellini E, Pia A, Brizzi MP, et al. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. Ann Oncol 2011; 22:988.</a></li><li><a class="nounderline abstract_t">Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30:134.</a></li><li><a class="nounderline abstract_t">Lee JS, Hirsh V, Park K, et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30:1114.</a></li><li><a class="nounderline abstract_t">Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012; 13:897.</a></li><li><a class="nounderline abstract_t">Chrisoulidou A, Mandanas S, Margaritidou E, et al. Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer. Onco Targets Ther 2015; 8:2435.</a></li><li><a class="nounderline abstract_t">Shen H, Yang Z, Zhao W, et al. Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance. Drug Metab Dispos 2013; 41:2095.</a></li><li><a class="nounderline abstract_t">Marcolino MS, Boersma E, Clementino NC, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol 2011; 22:2073.</a></li><li><a class="nounderline abstract_t">Gafter-Gvili A, Ram R, Gafter U, et al. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature. Leuk Res 2010; 34:123.</a></li><li><a class="nounderline abstract_t">Pou M, Saval N, Vera M, et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 2003; 44:1239.</a></li><li><a class="nounderline abstract_t">Cortes JE, Gambacorti-Passerini C, Kim DW, et al. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clin Lymphoma Myeloma Leuk 2017; 17:684.</a></li><li><a class="nounderline abstract_t">Yilmaz M, Lahoti A, O'Brien S, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 2015; 121:3894.</a></li><li><a class="nounderline abstract_t">Foringer JR, Verani RR, Tjia VM, et al. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother 2005; 39:2136.</a></li><li><a class="nounderline abstract_t">Penel N, Blay JY, Adenis A. Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med 2008; 358:2746.</a></li><li><a class="nounderline abstract_t">Gordon JK, Magid SK, Maki RG, et al. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). Leuk Res 2010; 34:827.</a></li><li><a class="nounderline abstract_t">Barta VS, Uppal NN, Pullman JM, et al. Nephrotoxicity Corner | Acute tubular injury associated with imatinib (Gleevec): a case report and review of the literature. Journal of Onco-Nephrology 2017; 1:1.</a></li><li><a class="nounderline abstract_t">Vidal-Petiot E, Rea D, Serrano F, et al. Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 2016; 16:169.</a></li><li><a class="nounderline abstract_t">Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006.</a></li><li><a class="nounderline abstract_t">O'Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009; 94:1131.</a></li><li><a class="nounderline abstract_t">Ozkurt S, Temiz G, Acikalin MF, Soydan M. Acute renal failure under dasatinib therapy. Ren Fail 2010; 32:147.</a></li><li><a class="nounderline abstract_t">Kaiafa G, Kakaletsis N, Savopoulos C, et al. Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report. J Clin Pharm Ther 2014; 39:102.</a></li><li><a class="nounderline abstract_t">Holstein SA, Stokes JB, Hohl RJ. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res 2009; 33:344.</a></li><li><a class="nounderline abstract_t">Martino S, Daguindau E, Ferrand C, et al. A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib. Leuk Res Rep 2013; 2:29.</a></li><li><a class="nounderline abstract_t">Uz B, Dolasik I. An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis. Leuk Res Rep 2016; 5:1.</a></li><li><a class="nounderline abstract_t">Wallace E, Lyndon W, Chumley P, et al. Dasatinib-induced nephrotic-range proteinuria. Am J Kidney Dis 2013; 61:1026.</a></li><li><a class="nounderline abstract_t">Hirano T, Hashimoto M, Korogi Y, et al. Dasatinib-induced nephrotic syndrome. Leuk Lymphoma 2016; 57:726.</a></li><li><a class="nounderline abstract_t">Koshida T, Wu S, Suzuki H, et al. Thrombotic microangiopathy in dasatinib-treated patients with chonic myeloid leukemia. J Onco-Nephrology 2019; 4:41.</a></li><li><a class="nounderline abstract_t">Adegbite BO, Abramson MH, Gutgarts V, et al. Patient-Specific Pharmacokinetics and Dasatinib Nephrotoxicity. Clin J Am Soc Nephrol 2023; 18:1175.</a></li><li><a class="nounderline abstract_t">Abbas A, Mirza MM, Ganti AK, Tendulkar K. Renal Toxicities of Targeted Therapies. Target Oncol 2015; 10:487.</a></li><li><a class="nounderline abstract_t">Calizo RC, Bhattacharya S, van Hasselt JGC, et al. Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity. Nat Commun 2019; 10:2061.</a></li><li><a class="nounderline abstract_t">Arai H, Yamamoto S, Matsubara T, et al. Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib. Intern Med 2023; 62:2693.</a></li><li><a class="nounderline abstract_t">Hurabielle C, Pillebout E, Stehlé T, et al. Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma. PLoS One 2016; 11:e0149873.</a></li><li><a class="nounderline abstract_t">Uthurriague C, Thellier S, Ribes D, et al. Vemurafenib significantly decreases glomerular filtration rate. J Eur Acad Dermatol Venereol 2014; 28:978.</a></li><li><a class="nounderline abstract_t">Regnier-Rosencher E, Lazareth H, Gressier L, et al. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas. Br J Dermatol 2013; 169:934.</a></li><li><a class="nounderline abstract_t">Launay-Vacher V, Zimner-Rapuch S, Poulalhon N, et al. Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer 2014; 120:2158.</a></li><li><a class="nounderline abstract_t">Jhaveri KD, Sakhiya V, Fishbane S. Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib. JAMA Oncol 2015; 1:1133.</a></li><li><a class="nounderline abstract_t">Teuma C, Perier-Muzet M, Pelletier S, et al. New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma. Cancer Chemother Pharmacol 2016; 78:419.</a></li><li><a class="nounderline abstract_t">Denis D, Franck N, Fichel F, et al. Fanconi syndrome induced by vemurafenib: a new renal adverse event. JAMA Dermatol 2015; 151:453.</a></li><li><a class="nounderline abstract_t">Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694.</a></li><li><a class="nounderline abstract_t">Maanaoui M, Saint-Jacques C, Gnemmi V, et al. Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: A case report. Medicine (Baltimore) 2017; 96:e7196.</a></li><li><a class="nounderline abstract_t">Perico L, Mandalà M, Schieppati A, et al. BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome. Am J Kidney Dis 2017; 70:145.</a></li><li><a class="nounderline abstract_t">Gogas HJ, Flaherty KT, Dummer R, et al. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. Eur J Cancer 2019; 119:97.</a></li><li><a class="nounderline abstract_t">Seethapathy H, Bates H, Chute DF, et al. Acute kidney injury following encorafenib and binimetinib for metastatic melanoma. Kidney Med 2020; 2:P373.</a></li><li><a class="nounderline abstract_t">Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018; 19:603.</a></li><li><a class="nounderline abstract_t">Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018; 19:1315.</a></li><li><a class="nounderline abstract_t">Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369:507.</a></li><li class="breakAll">Ibrutinib capsules. United States Prescribing Information. US National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44#section-2.3 (Accessed on November 19, 2013).</li><li><a class="nounderline abstract_t">Manohar S, Bansal A, Wanchoo R, et al. Ibrutinib induced acute tubular injury: A case series and review of the literature. Am J Hematol 2019; 94:E223.</a></li><li><a class="nounderline abstract_t">Mato AR, Woyach JA, Brown JR, et al. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med 2023; 389:33.</a></li><li><a class="nounderline abstract_t">Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17:425.</a></li><li><a class="nounderline abstract_t">Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375:1925.</a></li><li><a class="nounderline abstract_t">Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35:3638.</a></li><li><a class="nounderline abstract_t">Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375:1738.</a></li><li><a class="nounderline abstract_t">Turner NC, Ro J, André F, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373:209.</a></li><li><a class="nounderline abstract_t">Chappell JC, Turner PK, Pak YA, et al. Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther 2019; 105:1187.</a></li><li><a class="nounderline abstract_t">Rugo HS, Huober J, García-Sáenz JA, et al. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist 2021; 26:e522.</a></li><li><a class="nounderline abstract_t">Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res 2017; 23:5218.</a></li><li><a class="nounderline abstract_t">Tolaney S, Lam AQ, Mukundan S, et al. Abstract P6-15-01: Analysis of renal function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4 &amp; 6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC). Cancer Res 2017; 77S.</a></li><li><a class="nounderline abstract_t">Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97:1221.</a></li><li><a class="nounderline abstract_t">Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007; 8:387.</a></li><li><a class="nounderline abstract_t">Groenestege WM, Thébault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007; 117:2260.</a></li><li><a class="nounderline abstract_t">Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015; 16:763.</a></li><li><a class="nounderline abstract_t">Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013; 14:697.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658.</a></li><li><a class="nounderline abstract_t">Cao Y, Liao C, Tan A, et al. Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer. Chemotherapy 2010; 56:459.</a></li><li><a class="nounderline abstract_t">Vickers MM, Karapetis CS, Tu D, et al. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Ann Oncol 2013; 24:953.</a></li><li><a class="nounderline abstract_t">Vincenzi B, Santini D, Galluzzo S, et al. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res 2008; 14:4219.</a></li><li><a class="nounderline abstract_t">Vincenzi B, Galluzzo S, Santini D, et al. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann Oncol 2011; 22:1141.</a></li><li><a class="nounderline abstract_t">Cao Y, Liu L, Liao C, et al. Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. Cancer Chemother Pharmacol 2010; 66:37.</a></li><li><a class="nounderline abstract_t">Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11:689.</a></li><li><a class="nounderline abstract_t">Sasaki K, Anderson E, Shankland SJ, Nicosia RF. Diffuse proliferative glomerulonephritis associated with cetuximab, an epidermal growth factor receptor inhibitor. Am J Kidney Dis 2013; 61:988.</a></li><li><a class="nounderline abstract_t">Ito C, Fujii H, Ogura M, et al. Cetuximab-induced nephrotic syndrome in a case of metastatic rectal cancer. J Oncol Pharm Pract 2013; 19:265.</a></li><li><a class="nounderline abstract_t">Berardi R, Santoni M, Rinaldi S, et al. Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. PLoS One 2016; 11:e0152079.</a></li><li><a class="nounderline abstract_t">Kumasaka R, Nakamura N, Shirato K, et al. Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy. J Clin Oncol 2004; 22:2504.</a></li><li><a class="nounderline abstract_t">Maruyama K, Chinda J, Kuroshima T, et al. Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib. Intern Med 2015; 54:823.</a></li><li><a class="nounderline abstract_t">Kaneko T, Shimizu A, Aoki M, Tsuruoka S. A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma. CEN Case Rep 2015; 4:31.</a></li><li><a class="nounderline abstract_t">Degirolamo C, Sabbà C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 2016; 15:51.</a></li><li><a class="nounderline abstract_t">Nishina T, Takahashi S, Iwasawa R, et al. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors. Invest New Drugs 2018; 36:424.</a></li><li><a class="nounderline abstract_t">Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21:671.</a></li><li><a class="nounderline abstract_t">Nogova L, Sequist LV, Perez Garcia JM, et al. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. J Clin Oncol 2017; 35:157.</a></li><li class="breakAll">Javle MM, Roychowdhury S, Kelley RK, et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement (abstract). J Clin Oncol 39,2021 (suppl3; abstr 265). https://meetinglibrary.asco.org/record/194241/abstract (Accessed on June 02, 2021).</li><li><a class="nounderline abstract_t">Gile JJ, Ou F-S, Mahipal A, et al. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol 2021; 5:1228.</a></li><li class="breakAll">Pemigatinib. United States prescribing information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213736s001lbl.pdf (Accessed on March 02, 2021).</li><li><a class="nounderline abstract_t">Moktefi A, Saldana C, Stehlé T, et al. Acute tubular necrosis after selective FGFR tyrosine kinase inhibitor therapy. Eur J Cancer 2020; 139:177.</a></li><li><a class="nounderline abstract_t">Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2019; 381:338.</a></li><li><a class="nounderline abstract_t">Pal SK, Rosenberg JE, Hoffman-Censits JH, et al. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. Cancer Discov 2018; 8:812.</a></li><li><a class="nounderline abstract_t">Javle M, Lowery M, Shroff RT, et al. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol 2018; 36:276.</a></li><li><a class="nounderline abstract_t">Gottschalk I, Berg C, Harbeck N, et al. Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current Literature. Breast Care (Basel) 2011; 6:475.</a></li><li><a class="nounderline abstract_t">Bader AA, Schlembach D, Tamussino KF, et al. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 2007; 8:79.</a></li><li><a class="nounderline abstract_t">Watson WJ. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 2005; 105:642.</a></li><li><a class="nounderline abstract_t">Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18:732.</a></li><li><a class="nounderline abstract_t">Cosmai L, Gallieni M, Porta C. Renal toxicity of anticancer agents targeting HER2 and EGFR. J Nephrol 2015; 28:647.</a></li><li><a class="nounderline abstract_t">de Souza JA, Davis DW, Zhang Y, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2012; 18:2336.</a></li><li><a class="nounderline abstract_t">Stallone G, Infante B, Pontrelli P, et al. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation 2011; 91:997.</a></li><li><a class="nounderline abstract_t">Swaminathan S, Rosner MH. The podocyte under stress: AKT2 to the rescue. Am J Kidney Dis 2014; 63:555.</a></li><li><a class="nounderline abstract_t">Izzedine H, Boostandoot E, Spano JP, et al. Temsirolimus-induced glomerulopathy. Oncology 2009; 76:170.</a></li><li><a class="nounderline abstract_t">Izzedine H, Escudier B, Rouvier P, et al. Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven. Ann Oncol 2013; 24:2421.</a></li><li><a class="nounderline abstract_t">Bergsma H, Konijnenberg MW, van der Zwan WA, et al. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging 2016; 43:1802.</a></li><li><a class="nounderline abstract_t">Sabet A, Ezziddin K, Pape UF, et al. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. Eur J Nucl Med Mol Imaging 2014; 41:505.</a></li><li><a class="nounderline abstract_t">Mohan A, Herrmann SM. Capmatinib-Induced Pseudo-Acute Kidney Injury: A Case Report. Am J Kidney Dis 2022; 79:120.</a></li><li><a class="nounderline abstract_t">Paik PK, Felip E, Veillon R, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med 2020; 383:931.</a></li><li><a class="nounderline abstract_t">Dean E, Middleton MR, Pwint T, et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 2012; 106:468.</a></li><li><a class="nounderline abstract_t">Lazareth H, Delanoy N, Cohen R, et al. Nephrotoxicity Associated With Niraparib. Am J Kidney Dis 2020; 76:898.</a></li><li><a class="nounderline abstract_t">Gudsoorkar P, Wanchoo R, Jhaveri KD. Nirogacestat and Hypophosphatemia. Kidney Int Rep 2023; 8:1478.</a></li><li><a class="nounderline abstract_t">Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors. N Engl J Med 2023; 388:898.</a></li><li><a class="nounderline abstract_t">Vogl DT, Dingli D, Cornell RF, et al. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol 2018; 36:859.</a></li><li><a class="nounderline abstract_t">Chari A, Vogl DT, Gavriatopoulou M, et al. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med 2019; 381:727.</a></li><li><a class="nounderline abstract_t">Gavriatopoulou M, Chari A, Chen C, et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia 2020; 34:2430.</a></li><li><a class="nounderline abstract_t">Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2022; 387:495.</a></li><li><a class="nounderline abstract_t">Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725.</a></li><li><a class="nounderline abstract_t">Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013; 19:2048.</a></li><li><a class="nounderline abstract_t">Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507.</a></li><li><a class="nounderline abstract_t">Gutgarts V, Jain T, Zheng J, et al. Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. Biol Blood Marrow Transplant 2020; 26:1071.</a></li><li><a class="nounderline abstract_t">Krishnamoorthy S, Ghobadi A, Santos RD, et al. CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. Am J Transplant 2021; 21:809.</a></li><li><a class="nounderline abstract_t">Jhaveri KD, Rosner MH. Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know. Clin J Am Soc Nephrol 2018; 13:796.</a></li><li><a class="nounderline abstract_t">Gupta S, Seethapathy H, Strohbehn IA, et al. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. Am J Kidney Dis 2020; 76:63.</a></li><li><a class="nounderline abstract_t">Kanduri SR, Cheungpasitporn W, Thongprayoon C, et al. Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies. Kidney Int Rep 2021; 6:1416.</a></li><li><a class="nounderline abstract_t">Lee MD, Strohbehn IA, Seethapathy HS, et al. Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel. Am J Kidney Dis 2021; 77:990.</a></li><li><a class="nounderline abstract_t">Farooqui N, Sy-Go JPT, Miao J, et al. Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy. Mayo Clin Proc 2022; 97:1294.</a></li><li><a class="nounderline abstract_t">Belldegrun A, Webb DE, Austin HA 3rd, et al. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987; 106:817.</a></li><li><a class="nounderline abstract_t">Mercatello A, Hadj-Aïssa A, Négrier S, et al. Acute renal failure with preserved renal plasma flow induced by cancer immunotherapy. Kidney Int 1991; 40:309.</a></li><li><a class="nounderline abstract_t">Guleria AS, Yang JC, Topalian SL, et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol 1994; 12:2714.</a></li><li><a class="nounderline abstract_t">Memoli B, De Nicola L, Libetta C, et al. Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion. Am J Kidney Dis 1995; 26:27.</a></li></ol></div><div id="topicVersionRevision">Topic 114914 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25735315" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29318210" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521117" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24258622" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25436798" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33615078" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Acute Tubular Injury and Renal Arterial Myocyte Vacuolization Following Crizotinib Administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24001942" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24703892" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Crizotinib and renal insufficiency: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25436806" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25096999" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25756473" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Complex renal cysts associated with crizotinib treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27468827" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The renal effects of ALK inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27468827" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The renal effects of ALK inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28501140" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32996364" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lorlatinib induced proteinuria: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20019017" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20006922" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21889330" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20538785" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Bevacizumab increases risk for severe proteinuria in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23175623" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22949147" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28950290" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24621598" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23177514" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25500702" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25500702" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18270341" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18270341" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29433850" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33959820" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Lenvatinib-related renal microangiopathy: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332223" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Renal effects of anti-angiogenesis therapy: update for the internist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25981818" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19039026" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18179992" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Allergic interstitial nephritis possibly related to sunitinib use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470456" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Interstitial nephritis in a patient taking sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17215530" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sorafenib in advanced clear-cell renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21321087" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22025146" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22370318" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22898678" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26366098" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026623" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21310760" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19640584" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12916879" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28807791" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26217876" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16288076" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Acute renal failure secondary to imatinib mesylate treatment in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18565874" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Imatinib as a possible cause of severe rhabdomyolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19963273" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Nephrotoxicity Corner | Acute tubular injury associated with imatinib (Gleevec): a case report and review of the literature</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26795084" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16687713" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Altered bone and mineral metabolism in patients receiving imatinib mesylate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19174494" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20113282" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Acute renal failure under dasatinib therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24188312" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18835038" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24371772" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26870658" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23540262" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Dasatinib-induced nephrotic-range proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26436329" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Dasatinib-induced nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Thrombotic microangiopathy in dasatinib-treated patients with chonic myeloid leukemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37382967" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Patient-Specific Pharmacokinetics and Dasatinib Nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25922090" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Renal Toxicities of Targeted Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31053734" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36642524" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26930506" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24267914" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Vemurafenib significantly decreases glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23909652" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24737576" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26182194" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27371224" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25494458" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Fanconi syndrome induced by vemurafenib: a new renal adverse event.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23020132" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28640105" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28242136" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31437754" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Acute kidney injury following encorafenib and binimetinib for metastatic melanoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29573941" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30219628" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23782157" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23782157" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31148235" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Ibrutinib induced acute tubular injury: A case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37407001" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26947331" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959613" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Palbociclib and Letrozole in Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28968163" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27717303" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26030518" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30449032" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33660385" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28533223" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Abstract P6-15-01: Analysis of renal function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4&amp;6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16106027" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Cetuximab therapy and symptomatic hypomagnesemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17466895" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671655" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26045340" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23746666" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470858" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21088398" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23144444" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18594003" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115601" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19760217" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613446" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Epidermal growth factor receptor inhibition strategies in oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23474009" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Diffuse proliferative glomerulonephritis associated with cetuximab, an epidermal growth factor receptor inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23047237" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Cetuximab-induced nephrotic syndrome in a case of metastatic rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27167519" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15197213" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25832950" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28509266" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26567701" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28965185" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203698" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27870574" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27870574" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33011621" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Acute tubular necrosis after selective FGFR tyrosine kinase inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31340094" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29848605" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29182496" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22419904" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17196514" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15738038" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28526536" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26341657" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Renal toxicity of anticancer agents targeting HER2 and EGFR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22371453" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21364499" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24480654" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : The podocyte under stress: AKT2 to the rescue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19212144" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Temsirolimus-induced glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23798615" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27160225" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24196919" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34118303" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Capmatinib-Induced Pseudo-Acute Kidney Injury: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469185" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22223088" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32679152" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Nephrotoxicity Associated With Niraparib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37441471" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Nirogacestat and Hypophosphatemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36884323" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Nirogacestat, aγ-Secretase Inhibitor for Desmoid Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29381435" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31433920" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32094461" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35661166" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Teclistamab in Relapsed or Refractory Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21830940" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23344265" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25317870" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Chimeric antigen receptor T cells for sustained remissions in leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32088364" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33089906" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29523675" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31973908" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34013119" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33098925" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35787856" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3495213" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1942780" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Acute renal failure with preserved renal plasma flow induced by cancer immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7989949" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611264" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
